Postsynthetic Modification of Thermo-Treated Metal-Organic Framework for Combined Photothermal/Photodynamic Antibacterial Therapy.
Jiangrong LiQiuyang ZhangZhiwei ChenSiyu GuoJiangna GuoFeng YanPublished in: ACS applied materials & interfaces (2024)
Metal-organic frameworks (MOFs) are emerging porous materials that can serve as carriers of photosensitizers and photothermal agents. Meanwhile, a large number of active sites in MOFs endow them with the characteristics of modification by postsynthetic modification. Herein, a dual-modal PDT/PTT therapeutic agent HMIL-121-acriflavine-tetrakis (4-amoniophenyl) porphyrin (HMIL-ACF-Por), prepared by the postsynthetic modification of the MOF (HMIL-121), was reported for antibacterial applications. The prepared HMIL-ACF-Por enables the generation of abundant reactive oxygen species, including the superoxide anion radical (O 2 - ) and singlet oxygen ( 1 O 2 ), and thermal energy under 808 nm NIR laser irradiation. HMIL-ACF-Por showed good antibacterial ability against Escherichia coli and Staphylococcus aureus in vitro. Meanwhile, HMIL-ACF-Por can effectively inhibit the inflammatory response caused by bacterial infection and accelerate S. aureus -infected wound healing under laser irradiation owing to the synergistic effect of photodynamic therapy (PDT) and photothermal therapy (PTT). These results demonstrate that HMIL-ACF-Por is a promising PDT/PTT therapeutic agent. This work also contributes to offering an effective solution for treating bacterial infections and promotes the application of MOF-based materials in biomedicine.
Keyphrases
- metal organic framework
- photodynamic therapy
- wound healing
- fluorescence imaging
- inflammatory response
- staphylococcus aureus
- escherichia coli
- reactive oxygen species
- silver nanoparticles
- cancer therapy
- ionic liquid
- high speed
- stem cells
- anti inflammatory
- radiation induced
- mass spectrometry
- immune response
- biofilm formation
- cystic fibrosis
- essential oil
- hydrogen peroxide
- mesenchymal stem cells
- methicillin resistant staphylococcus aureus
- drug release
- candida albicans